Why VBHC still holds potential for life sciences

Breakline

Value-Based Healthcare (VBHC): will it ever live up to its high expectations? Impact Steward Daniël Brouwer has been involved in many VHBC initiatives. He believes it still holds immense potential, especially in life sciences. How can VBHC drive real benefits for companies in life sciences and help them to do better for patients, society, and the planet along the way?

1. Doing right is great for business

VBHC focuses on improving outcomes for patients, the planet, and healthcare professionals. This commitment to “doing good” isn’t just altruistic—it’s also profitable:

  • Consumer trust: a consumer study demonstrates they are more likely to forgive companies for mistakes or lapses in service if they believe the company is making a positive impact on society or the environment.
  • Employee engagement: employees who believe their company is making a positive societal impact are more likely to be engaged, more satisfied with their jobs and show increased productivity, as shown by Gallup‘s Workplace Study.
  • Talent retention: more than two-thirds of employees said in a study they would not leave an organisation that is committed to CSR initiatives, and little over half of millennials said they would choose to work for an organisation with a strong CSR commitment.

In today’s interconnected world, addressing sustainability and societal challenges requires collaboration – and VBHC provides an excellent framework for that.

2. From products to solutions

Nowadays, patients demand more than medication; they expect integrated, patient-centric solutions, much like they’ve come to expect seamless service in other industries. VBHC enables pharmaceutical companies to meet these expectations by shifting focus from delivering standalone products to creating full healthcare solutions.

The VBHC approach can help companies to live up to these needs:

  • Developing a deep understanding of patient needs and wants.
  • Collaborating with other players in the healthcare ecosystem to design patient-centric solutions.
  • Fostering strategic partnerships through transmural collaboration—aligning efforts across care settings.

With VBHC, medicine evolves from being the primary product to becoming part of a comprehensive, integrated healthcare solution.

3. Unlocking business value

VBHC isn’t just about improving patient outcomes; it also enhances key pharmaceutical business drivers:

  • Better patient engagement: Empowering patients as active participants in their health improves adherence, compliance, and persistence.
  • Stronger relationships: VBHC fosters deeper collaboration between pharmaceutical companies and hospitals, shifting towards a value-driven engagement model.

On average, VBHC projects run for 16 months and involve eight critical hospital stakeholders. This offers pharmaceutical ample opportunities for meaningful partnerships and long-term value creation.

Daniel Brouwer

“I still believe Value-Based Healthcare holds immense potential, especially for pharmaceutical companies.”

Daniël Brouwer, Impact Steward

Changing the game

In the past 10 years, I’ve experienced these benefits firsthand when guiding many partnerships between pharmaceutical companies and hospitals. Most delivered measurable benefits for patients, providers, and the planet while driving sustainable business growth. Companies willing to embrace VBHC will not only stay relevant but also lead the way in a rapidly evolving healthcare landscape.

More about VBHC?

Reach out if you want to discuss your specific situation or check out our in-depth article about Design Thinking and VBHC.

Curious what we can do for you?

Daniël Brouwer

daniel.brouwer@impactstewards.com